Literature DB >> 30864598

Impairment of the autophagy-related lysosomal degradation pathway by an anticancer rhenium(i) complex.

Liang He1, Zheng-Yin Pan, Wei-Wei Qin, Yi Li, Cai-Ping Tan, Zong-Wan Mao.   

Abstract

Lysosomes play a critical role in the autophagy process. The impairment of lysosomes can affect the degradation of autophagic cargo, leading to the blockage of autophagy at the lysosomal stage and subsequent cell death. Herein, two phosphorescent Re(i) tricarbonyl complexes (Re1 and Re2) bearing β-carboline derivatives have been synthesized and characterized. Both complexes show pH-dependent phosphorescence, which can be used to specifically image the lysosomes. Cytotoxicity assay shows that they exhibit high anticancer activity and are able to overcome cross-resistance to cisplatin. Re2 can induce autophagy, which is blocked at the lysosomal stage due to lysosomal dysfunction, such as the decrease of cathepsin B activity, subsequently leading to both autophagy and apoptosis dependent cell death. In vivo studies revealed that it could significantly inhibit tumor growth.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30864598     DOI: 10.1039/c9dt00322c

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  9 in total

1.  Mitochondria-targeted Re(I) complexes bearing guanidinium as ligands and their anticancer activity.

Authors:  Shu-Fen He; Nan-Lian Pan; Bing-Bing Chen; Jia-Xin Liao; Min-Ying Huang; Hai-Jun Qiu; Dong-Chun Jiang; Jun-Jie Wang; Jia-Xi Chen; Jing Sun
Journal:  J Biol Inorg Chem       Date:  2020-10-20       Impact factor: 3.358

2.  In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex.

Authors:  Chilaluck C Konkankit; A Paden King; Kevin M Knopf; Teresa L Southard; Justin J Wilson
Journal:  ACS Med Chem Lett       Date:  2019-04-23       Impact factor: 4.345

3.  Synthesis, Characterization and Antitumor Mechanism Investigation of Heterometallic Ru(Ⅱ)-Re(Ⅰ) Complexes.

Authors:  Xiurong Ma; Junjian Lu; Peixin Yang; Bo Huang; Rongtao Li; Ruirong Ye
Journal:  Front Chem       Date:  2022-05-27       Impact factor: 5.545

Review 4.  Target-specific mononuclear and binuclear rhenium(i) tricarbonyl complexes as upcoming anticancer drugs.

Authors:  Ajay Sharma S; Vaibhavi N; Binoy Kar; Utpal Das; Priyankar Paira
Journal:  RSC Adv       Date:  2022-07-14       Impact factor: 4.036

Review 5.  Challenges and opportunities in the development of metal-based anticancer theranostic agents.

Authors:  Shreyas P Vaidya; Shubhankar Gadre; Ravi Teja Kamisetti; Malay Patra
Journal:  Biosci Rep       Date:  2022-05-27       Impact factor: 3.840

Review 6.  Rhenium-Based Complexes and in Vivo Testing: A Brief History.

Authors:  Miles S Capper; Hollie Packman; Mark Rehkämper
Journal:  Chembiochem       Date:  2020-04-14       Impact factor: 3.164

Review 7.  Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy.

Authors:  Hui Shan Liew; Chun-Wai Mai; Mohd Zulkefeli; Thiagarajan Madheswaran; Lik Voon Kiew; Nicolas Delsuc; May Lee Low
Journal:  Molecules       Date:  2020-09-12       Impact factor: 4.411

Review 8.  Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives.

Authors:  Kevin Schindler; Fabio Zobi
Journal:  Molecules       Date:  2022-01-15       Impact factor: 4.411

Review 9.  Photoactive and Luminescent Transition Metal Complexes as Anticancer Agents: A Guiding Light in the Search for New and Improved Cancer Treatments.

Authors:  Brondwyn S McGhie; Janice R Aldrich-Wright
Journal:  Biomedicines       Date:  2022-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.